Keifei Mounjafei Tirzepatide Pen works by activating GIP and GLP-1 receptors, leading to increased insulin secretion, decreased glucagon release, slowed gastric emptying, and reduced food intake. Clinical trials have demonstrated its efficacy in improving glycemic control, fasting plasma glucose levels and body weight. Tirzepatide weight loss treatment is injected once a week to help you lose weight as part of a wider diet and exercise programme. Tirzepatide works by reducing your appetite and slowing down the movement of food from the stomach to the small intestine. This process helps to leave you feeling fuller for longer, making it easier to reduce your calorie intake. 
Mounjafei Dosing Information
Usual Adult Dose for Diabetes Type 2:
Initial dose: 2.5 mg under the skin (subcutaneously) once a week.
After 4 weeks: The dosage should be increased to 5 mg subcutaneously once a week.
If additional glycemic control is needed: The dosage should be increased in 2.5 mg increments after at least 4 weeks on the current dose.
Maximum dose: 15 mg subcutaneously once a week.
Comments: The 2.5 mg dosage is for starting of treatment and is not intended for glycemic control. The day of weekly administration can be changed, if necessary, as long as the time between the 2 doses is at least 3 days (72 hours).